Clinical Trials

20 enrolled

Multiple Myeloma

NCT05920876 2023-06-27

A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma

100 enrolled

Multiple Myeloma, Recurrence

NCT05271682 2023-05-16

A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma

40 enrolled

Multiple Myeloma

NCT04861480 2023-04-18

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

NCT05438394 2023-04-14

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM

24 enrolled

Multiple Myeloma

NCT05740891 2023-02-23

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

50 enrolled

Multiple Myeloma

NCT04309084 2023-02-16

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

29 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasm, Residual, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT04706936 2023-02-06

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

25 enrolled

Multiple Myeloma, Recurrence

NCT05698303 2023-01-26

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

12 enrolled

Multiple Myeloma

NCT05007418 2023-01-17

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

54 enrolled

Multiple Myeloma, Recurrence

NCT05266768 2022-11-30

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#

36 enrolled

Multiple Myeloma

NCT05549973 2022-09-22

Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma

32 enrolled

Multiple Myeloma

NCT04688853 2022-09-08

A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients

26 enrolled

Multiple Myeloma

NCT05363800 2022-07-29

Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

198 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT05412329 2022-07-26

Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

9 enrolled

Multiple Myeloma

NCT05325801 2022-04-13

A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma

9 enrolled

Multiple Myeloma

NCT05052970 2022-02-01

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

60 enrolled

Multiple Myeloma, Recurrence

NCT04818372 2021-11-12

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

87 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT04601935 2021-11-02

A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma

34 enrolled

Multiple Myeloma

NCT04984434 2021-07-30

Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

68 enrolled

Multiple Myeloma, Recurrence

NCT04003168 2021-03-01

Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma

Multiple Myeloma, Recurrence

NCT04558853 2021-02-17

Clinical Study of Autologous Natural Killer Cells in Multiple Myeloma

12 enrolled

Multiple Myeloma

NCT03716856 2020-10-08

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

11 enrolled

Multiple Myeloma

NCT03711864 2020-09-30

Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma

15 enrolled

Multiple Myeloma

NCT04537442 2020-09-03

Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

NCT04500431 2020-08-05

Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

Multiple Myeloma

NCT04275583 2020-06-17

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule

40 enrolled

Multiple Myeloma

NCT04295018 2020-03-04

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Multiple Myeloma

NCT03051841 2020-02-24

CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma

Multiple Myeloma

NCT03150316 2020-02-24

CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma

Multiple Myeloma

NCT03015922 2020-01-22

MUKeleven

4 enrolled

Multiple Myeloma

NCT04194931 2019-12-11

Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

20 enrolled

Multiple Myeloma, Recurrence

NCT03618602 2019-09-19

Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients

30 enrolled

Multiple Myeloma

NCT03815383 2019-07-05

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

12 enrolled

Multiple Myeloma, Recurrence

NCT03751293 2019-05-15

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Multiple Myeloma, Recurrence

NCT03093168 2019-02-27

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

Multiple Myeloma

NCT03672253 2018-12-14

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

20 enrolled

Multiple Myeloma

NCT03674463 2018-12-14

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Multiple Myeloma

NCT03767725 2018-12-10

Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

Multiple Myeloma

NCT02955810 2018-03-29

CyBorD-Dara

Multiple Myeloma

NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

36 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT02240537 2016-04-19

BBMPI03

MyeloidOther hematologic neoplasmPlasma cell

4 enrolled

Smoldering Multiple Myeloma, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02467647 2015-06-10

HLJDT-2016

500 enrolled

Multiple Myeloma

NCT00004036 2013-12-19

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

LymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cell

30 enrolled

Immunoglobulin Light-chain Amyloidosis, Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Precancerous Conditions, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Primary Myelofibrosis, Drug-Related Side Effects and Adverse Reactions

NCT00024063 2013-12-19

SU006668 in Treating Patients With Advanced Solid Tumors